Human CD133 Protein, His Tag
Human CD133, His Tag (CD3-H52H4) is expressed from human 293 cells (HEK293). It contains AA Gly 20 - His 865 (Accession #
Predicted N-terminus: Gly 20
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 97.2 kDa. The protein migrates as 90-110 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Less than 1.0 EU per μg by the LAL method.
>90% as determined by SDS-PAGE.
Delivered as bulk protein in a 0.2 μm filtered solution of 50 mM HEPES, 150 mM NaCl, DDM, CHS, pH7.5 with glycerol as protectant.
Contact us for customized product form or formulation.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
The product MUST be stored at -70°C or lower upon receipt; -70 °C for 3 months under sterile conditions.
This product is supplied as sterile liquid solution and shipped frozen with dry ice, please inquire the shipping cost.
Human CD133, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.
Immobilized Human CD133, His Tag (Cat. No.
CD3-H52H4) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-Human CD133 (133-3) Antibody, Human IgG1 with a linear range of 1-16 ng/mL (QC tested).
Prominin-1 is also known as CD133, Antigen AC133, PROM1, PROML1 and MSTP061. Is used as marker for hematopoietic stem and progenitor cells (HSPC) for somatic stem cell isolation. May play a role in cell differentiation, proliferation and apoptosis . Binds cholesterol in cholesterol-containing plasma membrane microdomains and may play a role in the organization of the apical plasma membrane in epithelial cells. During early retinal development acts as a key regulator of disk morphogenesis. Involved in regulation of MAPK and Akt signaling pathways. In neuroblastoma cells suppresses cell differentiation such as neurite outgrowth in a RET-dependent manner.
Clinical and Translational Updates
Promotion & Exhibitions
Accurately evaluate CAR expression level and CAR-T cell persistence in clinical trials
Request for Slides
bioSeedin webinar 17th——《GM-CSF Antibody for the Treatment of CRS in COVID-19》
Request for Slides
Drug Development Status
Number of Launched Drugs：0 Details
Number of Drugs in Clinical Trials：0 Details
Latest Research Phase：Preclinical
Datasheet & Documentation
+1 800-810-0816 (US)
+86 400-682-2521 (AP)
New Product Launch
Emerging VoCs, Lambda, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
SARS-CoV-2 Related Kits
ELISA kits for neutralizing antibody titer assay, binding antibody titer assay, antibody isotype assay, antigen titer assay and inhibitor screening, etc., which can accelerate the research and development of anti-SARS-CoV-2 drugs and vaccines.
Targets of CAR-T Cell Therapy
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
Full-length Transmembrane Proteins
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
Questions & Comments
This web search service is supported by Google Inc.